Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Return on Sales (2022 - 2025)

Atara Biotherapeutics' Return on Sales history spans 4 years, with the latest figure at 2.14% for Q4 2025.

  • For Q4 2025, Return on Sales fell 175.0% year-over-year to 2.14%; the TTM value through Dec 2025 reached 0.27%, up 93.0%, while the annual FY2025 figure was 0.27%, 93.0% up from the prior year.
  • Return on Sales reached 2.14% in Q4 2025 per ATRA's latest filing, down from 1.25% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.39% in Q1 2025 to a low of 337.43% in Q4 2022.
  • Average Return on Sales over 4 years is 37.19%, with a median of 1.69% recorded in 2025.
  • The largest YoY upside for Return on Sales was 32294bps in 2023 against a maximum downside of -9003bps in 2023.
  • A 4-year view of Return on Sales shows it stood at 337.43% in 2022, then skyrocketed by 96bps to 14.49% in 2023, then skyrocketed by 97bps to 0.38% in 2024, then plummeted by -456bps to 2.14% in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Return on Sales are 2.14% (Q4 2025), 1.25% (Q3 2025), and 0.14% (Q2 2025).